In our study, we found that the whole cohort of 21-OHD patients showed a statistically significant trend towards the reduction in the serum levels of ACTH, 17-OHP and Δ4-androstenedione, which are important indicators of the metabolic control of the disease, during the study period. The gene discussed is POMC; the disease is classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.